Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...
AbbVie’s newer immunology drugs are offsetting Humira’s decline, sending stock up 5%
AbbVie Inc.’s stock rose 5% early Friday to lead S&P 500 gainers premarket, after the drug company beat fourth-quarter ...
AbbVie expects Humira access to decrease throughout 2025
Says therapeutic portfolio ‘demonstrating very strong momentum’ into 2025. Says making “significant progress” in R&D efforts. Invest with ...
AbbVie Stock Soars as Biotech Tops Sales Estimates, Raises Outlook
AbbVie stock was one of the top gainers in the S&P 500 Friday morning as the biotech firm's fourth-quarter revenue exceeded ...
Earnings call transcript: AbbVie Q4 2024 beats expectations, stock surges
AbbVie Inc . (NYSE:ABBV) delivered strong financial results for Q4 2024, surpassing analysts' expectations with an earnings per share (EPS) of $2.16, compared to the forecast of $2.06. The company ...
Investing20h
US Dollar Index (DXY)
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
5 stocks to watch on Friday: XOM, ABBV, WBA and more
U.S. stock index futures were higher on Friday, as market participants digested a busy week with several developments on ...